PL392702A1 - Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna - Google Patents

Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna

Info

Publication number
PL392702A1
PL392702A1 PL392702A PL39270210A PL392702A1 PL 392702 A1 PL392702 A1 PL 392702A1 PL 392702 A PL392702 A PL 392702A PL 39270210 A PL39270210 A PL 39270210A PL 392702 A1 PL392702 A1 PL 392702A1
Authority
PL
Poland
Prior art keywords
nucleotide
nucleotide analog
analog
pharmaceutical composition
pro
Prior art date
Application number
PL392702A
Other languages
English (en)
Other versions
PL217694B1 (pl
Inventor
Adam Kraszewski
Joanna Romanowska
Agnieszka Szymańska-Michalak
Michał Sobkowski
Jerzy Boryski
Jacek Stawiński
Andrzej Lipniacki
Andrzej Piasek
Original Assignee
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Narodowy Instytut Leków
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Chemii Bioorganicznej Polskiej Akademii Nauk, Narodowy Instytut Leków filed Critical Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Priority to PL392702A priority Critical patent/PL217694B1/pl
Priority to PCT/PL2011/000103 priority patent/WO2012053917A1/en
Priority to EP11781885.6A priority patent/EP2630152B1/en
Priority to US13/879,709 priority patent/US9206209B2/en
Publication of PL392702A1 publication Critical patent/PL392702A1/pl
Publication of PL217694B1 publication Critical patent/PL217694B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy oraz kompozycja farmaceutyczna. Bardziej dokładnie wynalazek dotyczy nowej grupy pochodnych nukleotydowych oraz ich zastosowania w częściowym lub całkowitym hamowaniu namnażania ludzkiego wirusa niedoboru odporności (HIV).
PL392702A 2010-10-19 2010-10-19 Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna PL217694B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL392702A PL217694B1 (pl) 2010-10-19 2010-10-19 Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna
PCT/PL2011/000103 WO2012053917A1 (en) 2010-10-19 2011-10-13 Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition
EP11781885.6A EP2630152B1 (en) 2010-10-19 2011-10-13 Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition
US13/879,709 US9206209B2 (en) 2010-10-19 2011-10-13 Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL392702A PL217694B1 (pl) 2010-10-19 2010-10-19 Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna

Publications (2)

Publication Number Publication Date
PL392702A1 true PL392702A1 (pl) 2012-04-23
PL217694B1 PL217694B1 (pl) 2014-08-29

Family

ID=44936505

Family Applications (1)

Application Number Title Priority Date Filing Date
PL392702A PL217694B1 (pl) 2010-10-19 2010-10-19 Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna

Country Status (4)

Country Link
US (1) US9206209B2 (pl)
EP (1) EP2630152B1 (pl)
PL (1) PL217694B1 (pl)
WO (1) WO2012053917A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL238768B1 (pl) * 2017-07-31 2021-10-04 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Nowy analog nukleozydo difosforanu, kompozycja farmaceutyczna zawierająca analog nukleozydo difosforanu, jego zastosowanie i sposób syntezy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
CN1133642C (zh) 2000-10-09 2004-01-07 清华大学 核苷5’-硫代磷酰氨基酸酯化合物
RU2243972C1 (ru) 2003-06-26 2005-01-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Фосфорамидаты нуклеозидных аналогов - ингибиторы репродукции вируса иммунодефицита человека
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
EP2121717A4 (en) 2007-01-17 2013-05-29 Inst Rech S Cliniques De Montreal NUCLEOSIDE AND NUCLEOTIDE ANALOGUES WITH QUANTUMARY CARBON CENTERS AND USE METHOD
WO2008118879A2 (en) 2007-03-23 2008-10-02 Ardea Biosciences, Inc. Antiviral compositions comprising 2 compounds

Also Published As

Publication number Publication date
US20130316970A1 (en) 2013-11-28
WO2012053917A1 (en) 2012-04-26
EP2630152A1 (en) 2013-08-28
EP2630152B1 (en) 2014-11-26
US9206209B2 (en) 2015-12-08
PL217694B1 (pl) 2014-08-29

Similar Documents

Publication Publication Date Title
CY1121452T1 (el) Παραγωγα πουρινης για τη θεραπευτικη αντιμετωπιση ιικων λοιμωξεων
MX2009013349A (es) Compuestos quimicos.
CL2013002939A1 (es) Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
TN2010000212A1 (en) Inhibitors of human immunodeficiency virus replication
PH12013502033A1 (en) Pyrimidine derivatives for the treatment of viral infections
UA115311C2 (uk) Геміфумарат тенофовіру алафенаміду
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
MD20200093A2 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
EA201590862A1 (ru) Фармацевтические композиции
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
MX350810B (es) Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
BR112012025678A2 (pt) composição para inibição da transmissão do hiv, uso da mesma, métood para preparação da mesma e método para inibição de transmissão do hiv.
EA201101397A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
WO2012047267A3 (en) Polyvalent immunogen
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
PL392702A1 (pl) Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna
GB2463584A (en) Carbohydrate-lipid constructs and their use in preventing or treating viral infection
PH12013500558A1 (en) Solid state forms of a potent hcv inhibitor
PT2643460T (pt) Métodos, composições e kits para determinação do virus da imunodeficiência humana (vih)
EP2924121A4 (en) MOLECULES AS INHIBITORS OF THE HUMAN IMMUNE WEAKT-VIRUS TYPE 1 (HIV-1), METHOD FOR THE MANUFACTURE THEREOF AND APPLICATIONS THEREOF